ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: PP20

‘It Is Due to Stress’ – But Which Type of Stress? Cumulative childhood stress is a risk factor for autoimmune disease
Abstract Number: 1224

‘No Route Map’: The Complex Healthcare Journeys of People with Fibromyalgia – a Record Linkage Study in the UK
Abstract Number: 1346

“Finally, I Can Do Something About It Myself”: A Process Evaluation of the Plants for Joints Lifestyle Intervention
Abstract Number: 0213

“The Best Part Is Feeling Like I Could Go out There and Maybe Really Help Somebody”: Training Peer Coaches to Deliver the Moving Well Total Knee Replacement Telephone-Based Coaching Program
Abstract Number: 1231

[68Ga]- CPCR4 Trifluoroacetate PET/CT Imaging of Chemokine Receptor CXCR4- Expression in Systemic Sclerosis Related Interstitial Lung Disease
Abstract Number: 0001

12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT)
Abstract Number: 0580

18F-FDG PET-MR Characterization of Aortitis in the IL1rn-/- Mouse Model of Giant-Cell Arteritis
Abstract Number: 1414

2022 Revision of the ACR/EULAR Remission Criteria for Rheumatoid Arthritis
Abstract Number: 0812

3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-associated Periodic Syndromes (CAPS) – Data from the RELIANCE Registry
Abstract Number: 1433

A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Abstract Number: 0139

A Clinical Study Designed to Support a Demonstration of Interchangeability Between AVT02 and Reference Adalimumab (Humira®)
Abstract Number: 1316

A Cluster of Paget Disease of the Bone in Black or African American Patients in a Veteran Population
Abstract Number: 1853

A Comparitive Study of NLRP3- and NLRP12-autoinflammatory Disease
Abstract Number: 1687

A Core Inflammation Program Conserved Across Human and Murine Neutrophils
Abstract Number: 0856

A Cross-Sectional Description of Physical Activity (PA) in Children with Juvenile Idiopathic Arthritis (JIA): The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)

1
2
3
…
154
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].